CompletedNot Applicable

The Role of KL-6 in the Clinical Diagnosis of ILD

1,190 participantsStarted 2013-12

Plain-language summary

The purpose of the study is to evaluate the significance of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them to the clinical diagnostic criteria and other respiratory diseases. In addition, the study discusses the value of KL-6 levels in terms of ILD treatment effect evaluation through the detection of serum KL-6 levels before treatment and after treatment.

Who can participate

Age range14 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Serums from patients with ILD, pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and health * Serums from patients with ILD: before treatment and 30-90 days after treatment Exclusion Criteria: * Serums from patients with cancer * Serums with visible precipitate * Serums with floc

What they're measuring

The KL-6 concentration on the immune analyzer

Timeframe: The serum from patients with ILD will be collected for the duration of hospital stay, an average of 4 weeks

Trial details

NCT IDNCT02197364

SponsorShanghai Pulmonary Hospital, Shanghai, China

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2014-04

View on ClinicalTrials.gov More Interstitial Lung Disease trials